Illumina Core Illumina — Total Revenue decreased by 5.9% to $1.09B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.8%, from $1.04B to $1.09B. Over 4 years (FY 2021 to FY 2025), Core Illumina — Total Revenue shows relatively stable performance with a -1.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market adoption and demand for the company's core technology, while a decrease may signal market saturation or competitive pressure.
Represents the total gross income generated by the primary business segment responsible for sequencing instruments, cons...
Comparable to segment-level net revenue reported by other life science tools and diagnostics companies.
ilmn_segment_core_illumina_total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.13B | $1.11B | $1.19B | $1.22B | $1.16B | $1.11B | $1.07B | $1.08B | $1.16B | $1.11B | $1.10B | $1.06B | $1.09B | $1.08B | $1.10B | $1.04B | $1.06B | $1.08B | $1.16B | $1.09B |
| QoQ Change | — | -1.8% | +8.0% | +2.3% | -5.3% | -4.0% | -4.0% | +0.9% | +7.7% | -4.6% | -0.8% | -3.7% | +3.4% | -1.1% | +2.2% | -5.7% | +1.7% | +2.4% | +6.9% | -5.9% |
| YoY Change | — | — | — | — | +2.7% | +0.4% | -10.7% | -11.9% | +0.3% | -0.4% | +2.9% | -1.9% | -5.8% | -2.4% | +0.6% | -1.4% | -3.0% | +0.4% | +5.0% | +4.8% |